Live Oak Bancshares, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 3, 2026, reporting third-quarter and nine-month financial results for the period.
Innovative Industrial Properties, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 3, 2026, reporting net income of $31.9 million for the third quarter and $108.6 million for the nine-month period.
Teva Pharmaceutical Industries Limited filed its quarterly report on Form 10-Q with the SEC on November 3, 2026, covering the period ended September 30, 2026, and reporting 1,166,826,784 ordinary shares outstanding as of that date.
PennyMac Mortgage Investment Trust filed its quarterly report on Form 10-Q with the SEC on November 3, 2026, covering the period ended September 30, 2026, disclosing share counts, registered securities, and risk factors for the Maryland-based mortgage real estate investment trust.
Denali Therapeutics Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 3, 2026, reporting a third-quarter net income of $70.1 million driven by a $194 million gain on the sale of a priority review voucher.
SI-BONE, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 3, 2026, reporting 45,113,087 shares of common stock outstanding as of October 28, 2026.
Angi Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 3, 2026, reporting a net loss of $238,307 thousand for the first nine months of the year, driven in large part by a $225,628 thousand …
HNI Corporation, a Muscatine, Iowa-based manufacturer of workplace furnishings and residential building products, filed its quarterly report on Form 10-Q for the fiscal quarter ended October 3, 2026, with the Securities and Exchange Commission on November 3, 2026.
Atlantic Union Bankshares Corporation filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 3, 2026, reporting consolidated balance sheet data and disclosing key corporate developments including a new subordinated notes issuance and …
Rhythm Pharmaceuticals, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 3, 2026, reporting third-quarter net product revenue of $92.1 million and a net loss of $41.4 million.